Turn Therapeutics Inc.

Turn Therapeutics Inc. is a U.S.-based pharmaceutical and medical device development company built around a proprietary platform for formulating active ingredients in stable oil-based carriers. Its pipeline includes FDA-cleared medical devices, a device under De Novo review, and drug candidates in clinical and pre-clinical development for dermatology and other therapeutic areas.

0.87

0.87

— Turn Therapeutics Inc.
%
Medical devices35% FDA-cleared and in-development devices used for dermatology and related applications.
Drug candidates25% Pharmaceutical programs in clinical and pre-clinical development, including dermatology and intranasal assets.
Platform technology20% PermaFusion formulation technology used to stabilize polar APIs in oil-based carriers.
Licensing and collaboration20% Out-licensing, development partnerships, and strategic arrangements for product commercialization.

Turn Therapeutics primarily serves pharmaceutical and medical device partners, regulators, and ultimately patients and...

  • Licensing and commercialization partnersprimary

    Companies that license Turn's products or platform and handle manufacturing, sales, and distribution.

  • Healthcare providerssecondary

    Dermatology and other clinicians who prescribe or use the company's cleared or approved products.

  • Patientsprimary

    Individuals with eczema, onychomycosis, and other conditions targeted by the pipeline.

  • Medical device manufacturerssecondary

    Third parties that may produce or distribute licensed device products.

Turn Therapeutics is headquartered in the United States and develops products intended for U.S...

  • •Headquartered in the United States
  • •Primary regulatory pathway is through the FDA
  • •Products are intended for U.S. and international commercialization
  • •Partner-led distribution may expand reach beyond the U.S.
  • •No country revenue breakdown was disclosed in the excerpts

The company is focused on advancing its device and drug pipeline through clinical testing, regulatory submissions, and...

01
Regulatory advancementshort-term

Approval is the key gate to product sales and broader commercialization.

02
Clinical developmentshort-term

Clinical data supports approval, labeling, and partner interest.

03
Partner-led commercializationmedium-term

Third-party manufacturing and distribution can scale products faster than an internal buildout.

04
Platform expansionlong-term

A reusable formulation platform can support multiple products and indications.

Turn Therapeutics faces high regulatory and clinical development risk because its business depends on FDA clearances,...

critical

Regulatory approval risk

Products cannot be commercialized until FDA pathways are successfully completed.

Scope
FleX, eczema candidate, onychomycosis candidate
Materiality
high
high

Clinical development failure or delay

Trial outcomes determine whether the company can advance to later-stage development and approval.

Scope
Human eczema trial and planned Phase 3 programs
Materiality
high
high

Financing and dilution risk

The company expects to fund operations through equity, debt, and other capital sources.

Scope
Common stock issuances and financing agreements
Materiality
high
medium

Partner execution risk

Commercial success depends on third parties handling manufacturing, distribution, and sales.

Scope
Licensing and commercialization arrangements
Materiality
medium
medium

Competition and class-wide product risk

Competing therapies or device issues can affect adoption and regulatory expectations.

Scope
Dermatology and drug-delivery markets
Materiality
medium
Deferred revenue from license agreement
Can shift revenue recognition across periods
Revenue recognition under ASC 606
Affects timing and amount of reported revenue
Capitalized patent legal costs
Influences asset base and amortization expense
Stock-based compensation
Affects operating loss and equity dilution
Going-concern assessment
Signals financing dependence and survival risk

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

Vera Therapeutics, Inc.

VERA · Pharmaceutical Preparations

Dermata Therapeutics, Inc.

DRMA · Pharmaceutical Preparations

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

CERO THERAPEUTICS HOLDINGS, INC.

CERO · Biological Products, (No Diagnostic Substances)

: 29/04/2026